Goossens Lucas M A, Standaert Baudouin, Hartwig Nico, Hövels Anke M, Al Maiwenn J
Institute for Medical Technology Assessment, Erasmus University Medical Center, Rotterdam, The Netherlands.
Vaccine. 2008 Feb 20;26(8):1118-27. doi: 10.1016/j.vaccine.2007.11.070. Epub 2007 Dec 17.
The objective of this study was to estimate the cost-utility of mass vaccination of 0-4-year-old children with Rotarix in the Netherlands. We used a Markov process with Dutch data on incidence, resource use and costs (GP, hospitalisation, productivity loss and household costs) to compare vaccination to conventional treatment from a societal perspective. Utility loss due to rotavirus-induced diarrhoea was measured using EQ5D, with GPs and paediatricians serving as proxies to fill out the questions. As the costs of a vaccination course ranged from 90 euro to 100 euro per child, the cost-utility ratio varied from 21,900 euro to 35,076 euro per QALY gained. Based on the current study, it is clear that mass vaccination with Rotarix against rotavirus gastroenteritis can be attractive, from an economic and a health care perspective.
本研究的目的是评估在荷兰对0至4岁儿童大规模接种Rotarix疫苗的成本效益。我们使用了一个马尔可夫过程，结合荷兰关于发病率、资源使用和成本（全科医生诊疗、住院治疗、生产力损失和家庭成本）的数据，从社会角度比较接种疫苗与传统治疗方法。轮状病毒引起的腹泻导致的效用损失使用EQ5D进行测量，由全科医生和儿科医生作为代理人填写相关问题。由于每个儿童的疫苗接种疗程成本在90欧元至100欧元之间，每获得一个质量调整生命年的成本效益比在21,900欧元至35,076欧元之间。基于当前的研究，很明显，从经济和医疗保健角度来看，大规模接种Rotarix疫苗预防轮状病毒肠胃炎是有吸引力的。
